| Literature DB >> 21682903 |
Jun-Ichi Satoh1, Hiroko Tabunoki.
Abstract
BACKGROUND: MicroRNAs (miRNAs) mediate posttranscriptional regulation of protein-coding genes by binding to the 3' untranslated region of target mRNAs, leading to translational inhibition, mRNA destabilization or degradation, depending on the degree of sequence complementarity. In general, a single miRNA concurrently downregulates hundreds of target mRNAs. Thus, miRNAs play a key role in fine-tuning of diverse cellular functions, such as development, differentiation, proliferation, apoptosis and metabolism. However, it remains to be fully elucidated whether a set of miRNA target genes regulated by an individual miRNA in the whole human microRNAome generally constitute the biological network of functionally-associated molecules or simply reflect a random set of functionally-independent genes.Entities:
Year: 2011 PMID: 21682903 PMCID: PMC3130707 DOI: 10.1186/1756-0381-4-17
Source DB: PubMed Journal: BioData Min ISSN: 1756-0381 Impact factor: 2.522
Figure 1The pathways, diseases, and pathological events relevant to 232 miRNA target networks. Among 1,223 human miRNAs examined, Diana-microT 3.0 identified the set of reliable targets from 273 miRNAs. Among them, KeyMolnet extracted molecular networks from 232 miRNAs. The generated network was compared side by side with human canonical networks of the KeyMolnet library, composed of 430 pathways, 885 diseases, and 208 pathological events to identify the canonical network showing the most statistically significant contribution to the extracted network (see Table S1 for all the information). After top three pathways, diseases, and pathological events were individually totalized, the cumulated numbers of top 10 of (a) pathway, (b) disease, and (c) pathological event categories are expressed as a bar graph.
The large-scale human microRNA target networks
| MicroRNA | Number of Targets | Molecules in KeyMolnet Networks | Top Pathway | Score | p-Value | Top Disease | Score | p-Value | Top Pathological Event | Score | p-Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| hsa-let-7a | 244 | 1022 | Transcriptional regulation by p53 | 593 | 2.69E-179 | Viral myocarditis | 113 | 1.21E-34 | Cancer | 206 | 1.31E-62 |
| hsa-let-7b | 242 | 1016 | Transcriptional regulation by p53 | 594 | 1.83E-179 | Viral myocarditis | 113 | 9.32E-35 | Cancer | 206 | 7.66E-63 |
| hsa-let-7c | 243 | 1020 | Transcriptional regulation by p53 | 593 | 2.49E-179 | Viral myocarditis | 113 | 1.11E-34 | Cancer | 206 | 1.10E-62 |
| hsa-let-7d | 145 | 885 | Transcriptional regulation by RB/E2F | 836 | 2.18E-252 | Chronic myelogenous leukemia | 72 | 1.95E-22 | Cancer | 130 | 9.68E-40 |
| hsa-let-7e | 236 | 1111 | Transcriptional regulation by p53 | 575 | 8.90E-174 | Viral myocarditis | 116 | 1.20E-35 | Cancer | 175 | 1.86E-53 |
| hsa-let-7f | 244 | 1022 | Transcriptional regulation by p53 | 593 | 2.69E-179 | Viral myocarditis | 113 | 1.21E-34 | Cancer | 206 | 1.31E-62 |
| hsa-let-7g | 245 | 1022 | Transcriptional regulation by p53 | 593 | 2.69E-179 | Viral myocarditis | 113 | 1.21E-34 | Cancer | 206 | 1.31E-62 |
| hsa-let-7i | 245 | 1022 | Transcriptional regulation by p53 | 593 | 2.69E-179 | Viral myocarditis | 113 | 1.21E-34 | Cancer | 206 | 1.31E-62 |
| hsa-miR-9 | 352 | 1115 | Transcriptional regulation by PPARa | 340 | 5.28E-103 | Hepatocellular carcinoma | 72 | 1.69E-22 | Cancer | 171 | 3.50E-52 |
| hsa-miR-17 | 195 | 961 | Transcriptional regulation by RB/E2F | 971 | 3.27E-293 | Chronic myelogenous leukemia | 92 | 2.83E-28 | Cancer | 181 | 3.58E-55 |
| hsa-miR-19a | 226 | 1094 | Transcriptional regulation by RB/E2F | 760 | 2.10E-229 | Chronic myelogenous leukemia | 113 | 1.26E-34 | Cancer | 253 | 7.04E-77 |
| hsa-miR-19b | 225 | 1094 | Transcriptional regulation by RB/E2F | 760 | 2.10E-229 | Chronic myelogenous leukemia | 113 | 1.26E-34 | Cancer | 253 | 7.04E-77 |
| hsa-miR-20a | 165 | 1038 | Transcriptional regulation by RB/E2F | 856 | 1.64E-258 | Chronic myelogenous leukemia | 87 | 6.09E-27 | Cancer | 85 | 3.33E-26 |
| hsa-miR-20b | 198 | 981 | Transcriptional regulation by RB/E2F | 962 | 2.35E-290 | Chronic myelogenous leukemia | 98 | 3.39E-30 | Cancer | 183 | 6.98E-56 |
| hsa-miR-26a | 148 | 672 | Transcriptional regulation by RB/E2F | 919 | 1.76E-277 | Chronic myelogenous leukemia | 107 | 6.15E-33 | Cancer | 181 | 3.20E-55 |
| hsa-miR-26b | 148 | 672 | Transcriptional regulation by RB/E2F | 919 | 1.76E-277 | Chronic myelogenous leukemia | 107 | 6.15E-33 | Cancer | 181 | 3.20E-55 |
| hsa-miR-27a | 229 | 1192 | Transcriptional regulation by CREB | 1022 | 2.23E-308 | Chronic myelogenous leukemia | 95 | 1.96E-29 | Cancer | 194 | 3.05E-59 |
| hsa-miR-27b | 261 | 1337 | Transcriptional regulation by CREB | 1022 | 2.23E-308 | Chronic myelogenous leukemia | 94 | 4.51E-29 | Cancer | 211 | 4.11E-64 |
| hsa-miR-29a | 119 | 543 | Transcriptional regulation by Ets-domain family | 430 | 4.36E-130 | Glioma | 85 | 3.46E-26 | Cancer | 139 | 1.41E-42 |
| hsa-miR-29b | 118 | 578 | Transcriptional regulation by Ets-domain family | 422 | 1.15E-127 | Glioma | 82 | 1.55E-25 | Cancer | 146 | 1.44E-44 |
| hsa-miR-29c | 118 | 543 | Transcriptional regulation by Ets-domain family | 430 | 4.36E-130 | Glioma | 85 | 3.46E-26 | Cancer | 139 | 1.41E-42 |
| hsa-miR-30a | 455 | 1494 | Transcriptional regulation by RB/E2F | 777 | 9.43E-235 | Chronic myelogenous leukemia | 86 | 1.11E-26 | Cancer | 195 | 2.39E-59 |
| hsa-miR-30b | 455 | 1480 | Transcriptional regulation by RB/E2F | 781 | 1.08E-235 | Chronic myelogenous leukemia | 87 | 7.01E-27 | Cancer | 188 | 1.92E-57 |
| hsa-miR-30c | 454 | 1495 | Transcriptional regulation by RB/E2F | 778 | 6.13E-235 | Chronic myelogenous leukemia | 86 | 1.15E-26 | Cancer | 191 | 3.63E-58 |
| hsa-miR-30d | 452 | 1491 | Transcriptional regulation by RB/E2F | 778 | 7.28E-235 | Chronic myelogenous leukemia | 86 | 1.01E-26 | Cancer | 195 | 1.96E-59 |
| hsa-miR-30e | 455 | 1481 | Transcriptional regulation by RB/E2F | 780 | 1.29E-235 | Chronic myelogenous leukemia | 87 | 7.25E-27 | Cancer | 188 | 2.05E-57 |
| hsa-miR-32 | 261 | 905 | Transcriptional regulation by RB/E2F | 842 | 2.74E-254 | Gastric cancer | 80 | 8.85E-25 | Cancer | 157 | 4.19E-48 |
| hsa-miR-92a | 219 | 642 | Transcriptional regulation by MEF2 | 335 | 1.51E-101 | Viral myocarditis | 59 | 1.62E-18 | Epithelial-mesenchymal transition | 83 | 7.76E-26 |
| hsa-miR-92b | 258 | 701 | Transcriptional regulation by MEF2 | 328 | 1.59E-99 | Viral myocarditis | 60 | 1.23E-18 | Cancer | 94 | 3.97E-29 |
| hsa-miR-93 | 195 | 958 | Transcriptional regulation by RB/E2F | 972 | 2.37E-293 | Chronic myelogenous leukemia | 92 | 2.47E-28 | Cancer | 181 | 2.77E-55 |
| hsa-miR-96 | 142 | 688 | Transcriptional regulation by Ets-domain family | 407 | 3.42E-123 | Viral myocarditis | 36 | 1.06E-11 | Cancer | 106 | 1.37E-32 |
| hsa-miR-98 | 162 | 671 | Transcriptional regulation by Myb | 549 | 4.73E-166 | Viral myocarditis | 85 | 2.66E-26 | Cancer | 126 | 1.42E-38 |
| hsa-miR-101 | 188 | 806 | Transcriptional regulation by AP-1 | 492 | 1.10E-148 | Hepatocellular carcinoma | 70 | 6.40E-22 | Cancer | 127 | 4.26E-39 |
| hsa-miR-106b | 164 | 1028 | Transcriptional regulation by RB/E2F | 854 | 7.21E-258 | Chronic myelogenous leukemia | 87 | 5.48E-27 | Cancer | 85 | 2.93E-26 |
| hsa-miR-124 | 285 | 1346 | Transcriptional regulation by RB/E2F | 756 | 3.57E-228 | Chronic myelogenous leukemia | 83 | 9.34E-26 | Cancer | 185 | 1.90E-56 |
| hsa-miR-137 | 288 | 941 | Transcriptional regulation by MITF family | 339 | 1.19E-102 | Adult T cell lymphoma/leukemia | 66 | 1.30E-20 | Cancer | 179 | 1.00E-54 |
| hsa-miR-147 | 199 | 867 | Transcriptional regulation by RB/E2F | 805 | 4.06E-243 | Chronic myelogenous leukemia | 113 | 6.60E-35 | Cancer | 132 | 2.57E-40 |
| hsa-miR-153 | 154 | 1019 | Transcriptional regulation by Myb | 507 | 2.35E-153 | Multiple myeloma | 60 | 6.44E-19 | Cancer | 174 | 4.31E-53 |
| hsa-miR-218 | 155 | 830 | Transcriptional regulation by AP-1 | 344 | 2.28E-104 | Hepatocellular carcinoma | 69 | 1.63E-21 | Cancer | 136 | 1.52E-41 |
| hsa-miR-372 | 101 | 562 | Transcriptional regulation by RB/E2F | 1022 | 2.23E-308 | Chronic myelogenous leukemia | 85 | 1.90E-26 | Cancer | 144 | 2.75E-44 |
| hsa-miR-429 | 123 | 634 | Transcriptional regulation by RB/E2F | 918 | 2.45E-277 | Chronic myelogenous leukemia | 76 | 1.71E-23 | Cancer | 130 | 5.28E-40 |
| hsa-miR-495 | 156 | 601 | Transcriptional regulation by Ets-domain family | 431 | 2.14E-130 | Rheumatoid arthritis | 77 | 5.90E-24 | Adipogenesis | 79 | 1.32E-24 |
| hsa-miR-506 | 394 | 1536 | Transcriptional regulation by Ets-domain family | 317 | 4.69E-96 | Viral myocarditis | 99 | 1.73E-30 | Cancer | 172 | 1.43E-52 |
| hsa-miR-519a | 281 | 1256 | Transcriptional regulation by RB/E2F | 811 | 5.32E-245 | Chronic myelogenous leukemia | 106 | 1.34E-32 | Cancer | 220 | 8.03E-67 |
| hsa-miR-519b-3p | 281 | 1256 | Transcriptional regulation by RB/E2F | 811 | 5.32E-245 | Chronic myelogenous leukemia | 106 | 1.34E-32 | Cancer | 220 | 8.03E-67 |
| hsa-miR-519c-3p | 281 | 1256 | Transcriptional regulation by RB/E2F | 811 | 5.32E-245 | Chronic myelogenous leukemia | 106 | 1.34E-32 | Cancer | 220 | 8.03E-67 |
| hsa-miR-520a-3p | 184 | 690 | Transcriptional regulation by RB/E2F | 1022 | 2.23E-308 | Chronic myelogenous leukemia | 94 | 6.95E-29 | Cancer | 146 | 1.12E-44 |
| hsa-miR-520b | 182 | 690 | Transcriptional regulation by RB/E2F | 1022 | 2.23E-308 | Chronic myelogenous leukemia | 94 | 6.95E-29 | Cancer | 146 | 1.12E-44 |
| hsa-miR-520c-3p | 182 | 690 | Transcriptional regulation by RB/E2F | 1022 | 2.23E-308 | Chronic myelogenous leukemia | 93 | 9.28E-29 | Cancer | 145 | 1.77E-44 |
| hsa-miR-520d-3p | 183 | 690 | Transcriptional regulation by RB/E2F | 1022 | 2.23E-308 | Chronic myelogenous leukemia | 94 | 6.95E-29 | Cancer | 146 | 1.12E-44 |
| hsa-miR-520e | 184 | 690 | Transcriptional regulation by RB/E2F | 1022 | 2.23E-308 | Chronic myelogenous leukemia | 94 | 6.95E-29 | Cancer | 146 | 1.12E-44 |
| hsa-miR-603 | 252 | 1150 | Transcriptional regulation by Ets-domain family | 344 | 3.26E-104 | Multiple myeloma | 84 | 4.36E-26 | Cancer | 161 | 4.24E-49 |
Among 1,223 human miRNAs examined, Diana-microT 3.0 predicted reliable targets from 273 miRNAs. Among them, KeyMolnet extracted molecular networks from 232 miRNAs. The generated network was compared side by side with human canonical networks of the KeyMolnet library, composed of 430 pathways, 885 diseases, and 208 pathological events. The canonical pathways, diseases, and pathological events with the most statistically significant contribution to the extracted network are shown. The table contains only the large-scale miRNA target networks generated by importing targets greater than 100 per individual miRNA into KeyMolnet. See Additional file 1 for all the information on 232 miRNAs and their target networks.
Figure 2Molecular network of miR-15a targets. By the "neighboring" network-search algorithm, KeyMolnet illustrated a highly complex network of miR-15a targets that has the most statistically significant relationship with the pathway of 'transcriptional regulation by myb'. Red nodes represent miR-15a direct target molecules predicted by Diana-microT 3.0, whereas white nodes exhibit additional nodes extracted automatically from the core contents of KeyMolnet to establish molecular connections. The molecular relation is indicated by solid line with arrow (direct binding or activation), solid line with arrow and stop (direct inactivation), solid line without arrow (complex formation), dash line with arrow (transcriptional activation), and dash line with arrow and stop (transcriptional repression). The transcription factor myb is highlighted by a blue circle.
Figure 3Molecular network of miR-106b targets. By the "neighboring" network-search algorithm, KeyMolnet illustrated a highly complex network of miR-106b targets that has the most statistically significant relationship with the pathway of 'transcriptional regulation by Rb/E2F'. Red nodes represent miR-106b direct target molecules predicted by Diana-microT 3.0, whereas white nodes exhibit additional nodes extracted automatically from the core contents of KeyMolnet to establish molecular connections. The molecular relation is indicated by solid line with arrow (direct binding or activation), solid line with arrow and stop (direct inactivation), solid line without arrow (complex formation), dash line with arrow (transcriptional activation), and dash line with arrow and stop (transcriptional repression). The transcription factor E2F is highlighted by a blue circle.